Probiotics, zinc, inulin, and vitamin D as an ancillary treatment for patients with acute pharyngotonsillitis

I. La Mantia, M. Gelardi, S.E. Aragona, G. Cupido, G. Ciprandi, the Italian Study

Article ID: 5427
Vol 36, Issue 2S2, 2022
DOI: https://doi.org/10.23812/j.biol.regul.homeost.agents.202236.2S2.5
Received: 9 May 2022; Accepted: 9 May 2022; Available online: 9 May 2022; Issue release: 9 May 2022

Abstract

Acute pharyngotonsillitis is a common disease, mainly characterized by a sore throat. The diagnosis is usually performed on the clinical ground, and antibiotic therapy is frequently used in clinical practice on an empirical basis. Antibiotics frequently induce intestinal and respiratory dysbiosis associated with slow recovery. Therefore, probiotics are commonly prescribed in patients treated with antibiotics to restore the physiological microbiota. The current clinical experience was conducted in patients with acute pharyngotonsillitis and treated with antibiotics. All patients were treated with antibiotics and Abincol@for two weeks, then a subgroup (ratio 1:1) took a one-month course of Abincol Immuno® (Group A), the other patients served as control (Group B). Patients were evaluated at baseline (T0), at the end of antibiotic treatment (T1), at the end of the Abincol Immuno® course (T2), and at the end of 4-month follow-up (T3).Globally, 922 outpatients (mean age 46 years) were enrolled: 452 (49%) in Group A and 470 (51%) in Group B. At T2, Group A patients had a lower frequency of all symptoms. Both nutraceuticals were well tolerated. In conclusion, the present clinical experience demonstrated that immune manipulation with this innovative multi-component product might be considered an effective and safe therapeutic option in managing patients with acute pharyngotonsillitis and treated with antibiotics.


Keywords

acute pharyngotonsillitis;antibiotic therapy;dysbiosis;probiotics;zinc;inulin;vitamin.D


References

Supporting Agencies



Copyright (c) 2022 I. La Mantia, M. Gelardi, S.E. Aragona, G. Cupido, G. Ciprandi, the Italian Study Group on Upper Respiratory Infections




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).